Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

The Super Bowl aired a Hims & Hers commercial that is receiving backlash for its non-FDA approved weight loss drug. This drug ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...

Listen to more stories on the Noa app. The ad that Hims & Hers Health plans to air during the Super Bowl comes at you with rapid-fire visual overload—a giant jiggling belly, bare feet on scales ...

Hims & Hers makes its Super Bowl commercial debut in 2025 with a spot for the telehealth company's weight loss medications.

Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth ...

Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...